J B Chemicals & Pharmaceuticals Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q8jh01ny0ql141cyb1m9bxsa.pdf

Key Takeaways


Domestic Business & Portfolio Strategy

Chopra: "We are not into 15 categories of portfolio. We are into half a dozen. So, that helps us with now 3, 4 teams, one team focusing on chronic business, one team focusing on acute business, one team focusing on hospital and your overall business in respiratory and paediatrics."

Azmarda: Post-LOE Dynamics

Chopra: "Azmarda, right now, the competition is stiff. But I think the story would be very different in 6 months, where you will see selective players and being patient and looking at in terms of continuing to do what we have planned."

CMO & Lozenges Business

Khanna: "As far as North America is concerned, yes, a long-term view on that, but too early to comment on what exactly will be our strategy there. Also please note, we have always maintained like Nikhil mentioned earlier, we operate in the medicated lozenges space, right? We don't want to do conventional lozenges."

International Markets


Margins, Costs & Balance Sheet

Chopra: "Going ahead for next couple of years, we are revising our EBITDA margin guidance from 24% to 26% to 25% to 27%. That is what we would like to share."

M&A & Portfolio Shaping


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin25%-27% (revised from 24%-26%)Next couple of years
Gross marginCloser to 65%FY24, if conditions hold
Debt repaymentTurn cash positive / zero debtBy Q3 FY24
ROCE25%-26%, then 30%+End of next fiscal; ~3 years
Chronic share60%Medium term
CMO growthLow double-digit to mid-teensFY24
South Africa lozenge launchHome-market launchQ2 FY24
New lozenge categoriesSleep, anti-inflammatory, immunityQ4 FY24
Overall business growth12%-14% revenue; 16%-18% EBITDAFY24
Azmarda competitive landscape"Story would be very different" with selective players~6 months

Key Metrics

MetricQ4 FY23
Revenue₹762 cr, +22% YoY
Full-year revenue₹3,149 cr, crossing ₹3,000 cr milestone
Domestic formulation revenue₹380 cr, +29% YoY; full year ₹1,640 cr, +38%
Gross margin63.9%, vs 65.9% in Q4 FY22; sequential improvement from 62.3% in Q3
Operating EBITDA (before ESOP)₹181 cr, +21% YoY; margin flat vs Q4 FY22
Operating EBITDA margin guidance25%–27%, revised from 24%–26% for next couple of years
Profit after tax₹88 cr, +4% YoY; full year ₹410 cr
Effective tax rate26% for FY23
Operating cash flow₹626 cr for FY23, vs ₹170 cr in FY22
Net debt₹266 cr, improved from ₹429 cr in Dec '22
Net working capital days89 days, improved from 111 days in FY22
CMO business revenue₹406 cr for FY23, +60% YoY; Q4 growth +18%
Domestic business growth vs IPM22% vs IPM growth of 8% (IQVIA MAT March 2023)
Chronic portfolio growth24% in FY23 vs 11% IPM chronic growth
MR productivity₹6.2 lakhs in FY23, up from ₹5.4 lakhs in FY22
MR count~2,200
Chronic revenue share~53%
Azmarda IQVIA rank#261, gained 125 ranks (MAT March 2023)
Azmarda volume trendUp ~20% in recent months vs pre-exclusivity period
Acquired portfolio quarterly revenue~₹80 cr
ROCE~21% in FY23; target 25%–26% by end of next fiscal, 30%+ in ~3 years
Revenue growth guidance12%–14% for next couple of years
EBITDA growth guidance16%–18% for next couple of years